Smarter. Stronger. Together: Achieving Quality HER2-Positive Breast Cancer Care by Educating Providers and Patients

Download All
Get up to date on key topics in the management of patients with HER2-positive breast cancer with downloadable slides and an on-demand webcast from a live webinar, expert commentaries and a podcast on HER2-positive breast cancer, and an updated Interactive Decision Support Tool for HER2-positive MBC.
Sara Hurvitz, MD, FACP
Program Director
Aditya Bardia, MD, MPH
Erika P. Hamilton, MD
Sara Hurvitz, MD, FACP
Komal Jhaveri, MD
Kristi Kay Orbaugh, MSN, NP, AOCNP
Danielle Roman, PharmD, BCOP
Sara Tolaney, MD, MPH
Aditya Bardia, MD, MPH
Sara Hurvitz, MD, FACP
Komal Jhaveri, MD
Heather McArthur, MD, MPH
Sara Tolaney, MD, MPH

On-Demand Webcast

In this on-demand webcast of a live symposium, expert faculty use case studies to highlight the latest safety and efficacy evidence supporting optimal management of patients with HER2-positive breast cancer.

Sara Hurvitz, MD, FACP
Program Director
Aditya Bardia, MD, MPH Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: April 28, 2022 Expired: April 27, 2023

ClinicalThought

In this commentary, 2 oncologists, an oncology nurse, and a pharmacist discuss how recent data on HER2-targeted treatment are changing the therapeutic paradigm in early and metastatic breast cancer.

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP Released: May 10, 2022

Sara Tolaney, MD, MPH, reviews recent clinical trial data showing survival benefits from newer targeted agents in the setting of HER2-positive, advanced breast cancer with brain metastases.

Sara Tolaney, MD, MPH Released: January 3, 2023

Downloadable Slideset

Download these slides summarizing key points from a live Cancer Conversations webinar on optimizing the management of patients with HER2+ breast cancer using currently available HER2-directed therapies.

Sara Hurvitz, MD, FACP
Program Director
Aditya Bardia, MD, MPH Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP
Released: March 30, 2022

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with HER2+ MBC with those of 5 renowned experts.

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Komal Jhaveri, MD Heather McArthur, MD, MPH Sara Tolaney, MD, MPH Released: November 23, 2022

Podcast

Listen in as expert faculty discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer, as well as potential implications of new data in clinical practice.

Erika P. Hamilton, MD Komal Jhaveri, MD Released: July 28, 2022

Download these slides summarizing key points from a recent podcast with expert discussion on key insights and the most recent data for the management of patients with HER2-positive breast cancer.

Erika P. Hamilton, MD Komal Jhaveri, MD Released: September 13, 2022
Provided by Clinical Care Options, LLC in partnership with Smart Patients.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Puma Biotechnology, Inc.
Seagen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings